Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to -$3000.0.

  • Fennec Pharmaceuticals' Other Non Operating Income changed N/A to -$3000.0 in Q3 2025 from the same period last year, while for Jun 2025 it was $3000.0, marking a year-over-year increase of 10468.75%. This contributed to the annual value of -$82000.0 for FY2024, which is 174000.0% down from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Other Non Operating Income stood at -$3000.0 for Q3 2025.
  • Fennec Pharmaceuticals' Other Non Operating Income's 5-year high stood at $17000.0 during Q2 2025, with a 5-year trough of -$38000.0 in Q1 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' median Other Non Operating Income value was -$3000.0 (recorded in 2022), while the average stood at -$4066.7.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Other Non Operating Income surged by 40000.0% in 2023 and then tumbled by 145000.0% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Other Non Operating Income stood at -$1000.0 in 2021, then crashed by 300.0% to -$4000.0 in 2022, then skyrocketed by 150.0% to $2000.0 in 2023, then plummeted by 1450.0% to -$27000.0 in 2024, then soared by 88.89% to -$3000.0 in 2025.
  • Its last three reported values are -$3000.0 in Q3 2025, $17000.0 for Q2 2025, and $13000.0 during Q1 2025.